Privacy Policy

Pursuant to the legislation applicable to the protection of personal data (“Privacy Legislation”) including EU Regulation 2016/679 (“GDPR”), Recordati Industria Chimica e Farmaceutica S.p.A provides some information necessary to illustrate how personal data will be processed through the following domain recordati.com.


  1. Data Controller
    Recordati Industria Chimica e Farmaceutica S.p.A. parent company of the Recordati Group, with registered office in Milano, Via M. Civitali n. 1, enrolled in the Register of Companies of Milan under number 00748210150 is the Data controller (hereinafter, the “Data Controller” or “Recordati“). 
  2. The Data Protection Officer of the Recordati Group can be contacted using the following contact details: Data Protection Officer – DPO, Recordati S.p.A., Via Matteo Civitali 1, Milan – Italy; e-mail: .

  3. Data Processed
    The data which will be processed include:

    Navigation data: language set in the user’s browser, name of the page the user viewed, screen resolution of the device the user is using, the Matomo ID that associates the hit with the right Analytics account, location of the user, characteristics of the browser, operating system and internet provider used by the user,  source/media that directed the user to the Website;

    Other data freely provided by users to access certain freely chosen services. Specific information notices and requests for consent, where required, can be found on the relevant sections of the Website.

  4. Purposes and legal bases of the processing
    Navigation data are used to allow the navigation of the Website and use its features, as well as to obtain anonymous statistical information on the use of the Website, to check its correct functioning and to identify anomalies and/or abuses.

    The legal basis of the processing is our legitimate interest to allow the proper functioning of the Website and to constantly improve its quality and attractiveness for users (Article 6.1. lett. f) GDPR). Based on our assessments, we believe that no interest, right or fundamental freedom of users prevail over this legitimate interest.

  5. Data Recipients – Data Transfer to Third Countries/International Organizations

    As part of the data processing for the purpose referred to in paragraph above, the data may be disclosed or otherwise made accessible to the companies belonging to the Recordati Group and to third parties such as.

    Where necessary, the Data Controller will appoint third parties as its Data Processors pursuant to Article 28 of the GDPR.

    Data will not be transferred outside the Economic European Area. This said, any Data transfer outside the Economic European Area will be carried out in compliance with the applicable provisions of GDPR.

  6. Data retention period
    Navigation data will be stored for 2 years from the relative registration. Only in the event of a request by the Public Authorities, the data may be stored for a longer period, in accordance with what will be ordered to the Data Controller.
  7. Data subject rights
    Users will always have, in accordance with the law, the right to withdraw at any time their consent, where given, as well as to exercise, at any time, the following rights:
    1. the “right of access” i.e. the right to obtain confirmation as to whether or not personal data concerning the User are being processed and the communication of such data in an intelligible form;
    2. the “right to rectification” i.e. the right to request the rectification or, if interested, the integration of personal data;
    3. the “right to erasure” e. the right to request the erasure or the anonymization of personal data that have been processed unlawfully, including data whose storage is unnecessary for the purposes for which they were collected or further processed;
    4. the “right to restriction of processing” e. the right to obtain from the Data Controller the limitation of the processing in certain cases provided for under the Privacy Legislation;
    5. the right to request the Data Controller to indicate the recipients to whom it has notified any rectification or erasure or restriction of processing (carried out in accordance with Articles 16, 17 and 18 GDPR, in fulfillment of the notification obligation unless this proves impossible or involves disproportionate effort);
    6. the “right to data portability” e. the right to receive (or transmit directly to another data controller) personal data in a structured, commonly used and machine-readable format;
    7. the “right to object”, i.e. the right to object, in whole or in part:
      • the processing of personal data carried out by the Data Controller for its own legitimate interest;
      • the processing of personal data carried out by the Data Controller for direct marketing or profiling purposes.

In the above cases, where necessary, the Data Controller will inform the third parties to whom the users personal data has been disclosed of the their exercise of rights, unless it is not possible or is too onerous and, in any case, in accordance with the provisions of the Privacy Legislation.

Where processing is based on consent, the user is also entitled to withdraw, at any time, any consent given, whereby it is understood that the withdrawal of consent shall not affect the lawfulness of the processing based on consent given prior to the withdrawal.


Users are entitled to exercise their rights at any time by using the contact details indicated in section 1 above or by writing to the DPO by e-mail at the following address: .


The Data Controller hereby informs users that, pursuant to the Privacy Legislation, they have the right to lodge a complaint with the competent supervisory authority (in particular in the Member State of User’s habitual residence, place of work or place of the alleged breach), if they are of the opinion that their personal data are being processed in a way that would lead to breaches of the GDPR.


In order to facilitate the exercise of the right to lodge a complaint, the name and contact details of the European Union Supervisory Authority are available at the following link: https://ec.europa.eu/justice/article-29/structure/data-protection-authorities/index_en.htm.


The Data Controller reserves the right to modify or simply update the content of this privacy policy, in part or in full, also due to changes in applicable legislation. We, therefore, invite you to regularly visit this section for the most recent and updated version of this privacy policy.


Edition: July 2023

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

Recordatirarediseases.comを離れます。

このサイトを離れ、別の外部サイトへ移動しようとしています。

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

あなたは医療関係者ですか?

このページでは、国内の医療関係者(医師・薬剤師等)の方を対象に情報を提供しています。一般の方や国外の医療関係者に対するものではございませんのでご了承ください。
Recordati for the planet
A clean environment is essential for people’s well-being: the health of the planet and the health of people is tightly interconnected. Environmental elements, such as air, water, land and climate, all have an impact on the well-being of humans. Placing a focus on people’s health and being sustainable therefore also means prioritising environmental protection and a responsibility towards future generations. This is why the Group ensures that it conducts business in a socially responsible manner and in accordance with sustainable practices, national and international laws, and the expectations of stakeholders.
Recordati for the community
We believe that contributing to the well-being of the community and dedicating part of our resources to acts of solidarity is not merely the fulfilment of company obligations or professional duty, but rather a moral imperative, an essential part of a healthy business capable of growth but at the same time able to support and develop the community in which it operates and make its employees proud.
Value and diversity of our people
At Recordati, we believe in equal opportunities and we guarantee that everyone can achieve their potential. We see diversity as a value and will not tolerate any discrimination based on ethnicity, nationality, gender, sexual orientation, disability, age, political or religious belief, or any other personal characteristics. At Recordati, we work hard to create a safe and inclusive work environment, where we all have our rights to physical and psychological integrity respected on a daily basis, as well as our right to freedom of opinion and association. We recognise that we each have a role to play in the success of our business and we implement staff development policies through which everyone’s contribution and achievements can be appropriately rewarded.
Multiple opportunities
Recordati is uniquely structured to bring treatment options across specialty and primary care, consumer healthcare, and rare diseases. We have fully integrated operations across research and development, chemical and finished product manufacturing through to commercialisation and licensing.
Luigi Longinotti
Managing Director and General Manager EMEA

Luigi Longinotti is Managing Director and General Manager for EMEA at Recordati Rare Diseases, leading the European and Middle Eastern Commercial Operations. He is responsible for Marketing, Medical, Market Access, Regulatory, Manufacturing and Logistics, as well as the enabling functions to support the business, including Compliance and Quality.

 

He joined Recordati in July 2014 as Corporate Portfolio Management Director for Orphan Drugs. In such a role he has been responsible for driving the growth of the rare disease portfolio at Recordati, with his duties ranging from business development to strategic marketing and pipeline project management.

 

Before he joined Recordati, he held senior business and corporate development roles at Chiesi Farmaceutici and Menarini Group where he executed several key asset deals and transactions.

Luigi gained a degree in Economics from the University of Florence and a Master’s degree in Business Innovation from Sant’Anna School of Advanced Studies in Pisa.

Bruno Parenti
Head of LAC Region, Head of Global Endocrinology Franchise

Bruno Parenti is Head of LAC Region at Recordati Rare Diseases, leading the business in Latin America, Asia Pacific and Russia. He has been in this position since 2011, where he spearheaded the expansion of operations around the globe. He recently assumed the additional role of Head of Global Endocrinology Franchise, establishing the new HQ in Basel and building a dedicated organization.

 

Prior to these positions, Bruno spent two years at Recordati Ireland overseeing international sales in the Asia-Pacific region. He served at Chiesi Farmaceutici for two years as Area Manager for the Far East. Earlier in his career, he held commercial roles at Kedrion Biopharmaceuticals where he was responsible for international markets with a focus on Latin America and the Middle East.

Mohamed Ladha
President and General Manager, North America

Mohamed Ladha is the President and General Manager at Recordati Rare Diseases where he is   responsible for the US and Canadian business. During his career,  Mohamed has held numerous leadership positions globally in hematology/oncology and specialty care to oversee business in the US, Canada, EU, China, Emerging Markets, and Japan.

 

Mohamed  joins Recordati Rare Diseases from Oncopeptides, where he was the General Manager and Executive Vice President for the US Region Business Unit. Prior to Oncopeptides, he served in a series of leadership positions of increasing responsibility at companies including Vertex Pharmaceuticals, Pfizer, Schering-Plough, Merck & Company, Hospira, ARIAD Pharmaceuticals, Takeda Oncology, and Tocagen. He started his career in basic science research focused in oncology at the Dana-Farber Cancer Institute.

 

Mohamed graduated from Hampshire College with a Bachelor of Arts degree. He also holds professional/graduate degrees from Harvard University’s Kennedy School of Government and Northwestern University’s Kellogg School of Management.

 

Changing to first name to be consistent with bio below, also feel that first name as opposed to Mr has a more informal and friendly tone.   [EC1]

Scott Pescatore
Executive Vice President

Scott Pescatore is Vice President and Head of Global Operations at Recordati Rare Diseases.

He holds a Doctor of Pharmacy degree and completed his post-doctoral fellowship in Pharmacology and Drug Development. Dr Pescatore has spent over 20 years working internationally in the pharmaceutical industry, specializing in oncology, haematology and rare diseases.

 

He joined Novartis Oncology US in 2001 where he served in various medical, sales and marketing roles of increasing responsibility. In 2008, he moved to Novartis Oncology UK as Business Franchise Head for solid tumours where he also managed the New Products portfolio. In 2010 he moved to Milan to manage the Region Europe Haematology Franchise where he led the joint venture between Novartis Oncology and Incyte to launch a novel treatment for myeloproliferative disorders. In 2014 he was appointed the Oncology General Manager in Ireland and after three years returned to Milan as General Manager of the Region Europe Rare Disease Business Unit, overseeing operations in 37 markets and focusing on the endocrinology portfolio.

 

Prior to joining Recordati Rare Diseases in 2020, he was Vice President Oncology Business Unit for AstraZeneca Italy where he was responsible for the portfolio of oncology/haematology products including two joint ventures with MSD and Daiichi Sankyo.

You are about to leave this site and visit the recordati global website?

To continue please click the link below.